Korro Bio (KRRO) Assets Average (2019 - 2026)
Korro Bio's (KRRO) quarterly Assets Average came in at $148.6 million in Q1 2026, down 30.65% YoY from $214.2 million in Q1 2025, and up 8.02% on a QoQ basis from $137.5 million in Q4 2025.
Korro Bio (KRRO) Assets Average (2019 - 2026) Analysis & Trends
Korro Bio (KRRO) has 8 years of Assets Average data on file, last reported at $148.6 million in Q1 2026.
- Quarterly Assets Average fell 30.65% year-over-year to $148.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.6 million (down 30.65% YoY) and the FY2025 annual result came in at $169.9 million, down 24.15% from the prior year.
- Assets Average improved to $148.6 million in Q1 2026, from $137.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $246.6 million in Q3 2024 to a low of $62.9 million in Q3 2023.
- A 5-year average of $160.8 million and a median of $157.3 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average sank 55.99% — and 2024, when it soared 292.21%.
- Tracing KRRO's Assets Average over 5 years: stood at $104.9 million in 2022, then grew by 27.77% to $134.0 million in 2023, then jumped by 75.28% to $234.9 million in 2024, then plunged by 41.45% to $137.5 million in 2025, then increased by 8.02% to $148.6 million in 2026.
- The last three Assets Average figures came in at $148.6 million (Q1 2026), $137.5 million (Q4 2025), and $171.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 173.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 173.53 Mn |
| Mar 31, 2026 | 148.56 Mn |
| Dec 31, 2025 | 137.53 Mn |
| Sep 30, 2025 | 170.99 Mn |
| Jun 30, 2025 | 191.32 Mn |
| Mar 31, 2025 | 214.22 Mn |
| Dec 31, 2024 | 234.89 Mn |
| Sep 30, 2024 | 246.57 Mn |
| Jun 30, 2024 | 223.79 Mn |
| Mar 31, 2024 | 209.82 Mn |
| Dec 31, 2023 | 134.01 Mn |
| Sep 30, 2023 | 62.87 Mn |
| Jun 30, 2023 | 90.44 Mn |
| Mar 31, 2023 | 87.62 Mn |
| Dec 31, 2022 | 104.88 Mn |
| Sep 30, 2022 | 142.84 Mn |
| Jun 30, 2022 | 157.30 Mn |
| Mar 31, 2022 | 175.15 Mn |
| Dec 31, 2021 | 193.77 Mn |
| Sep 30, 2021 | 211.20 Mn |